Perspective Therapeutics
CATX
97 hedge funds and large institutions have $146M invested in Perspective Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 24 closing their positions.
19,000% more call options, than puts
Call options by funds: $382K | Put options by funds: $2K
82% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 22
52% more capital invested
Capital invested by funds: $96.4M → $146M (+$49.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.9% less ownership
Funds ownership: 61.14% → 57.23% (-3.9%)
13% less funds holding
Funds holding: 112 → 97 (-15)
63% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.56M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.78M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.78M |
| 4 |
JP Morgan Chase
New York
|
+$1.07M |
| 5 |
BlackRock
New York
|
+$852K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.03M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$4.79M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$3.1M |
| 4 |
VC
Vestor Capital
Chicago,
Illinois
|
-$2.57M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.62M |
CATX Hedge Fund Activity: Q2 2025 in Review
97 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2025, worth a combined $146M — up 52% from $96.4M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CATX and 9 opened new positions — a net loss of 15 holders — while 22 trimmed existing stakes and 40 added.
The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.03M sold.
- 97 institutional investors held Perspective Therapeutics (CATX) as of Q2 2025, down from 112 in Q1 2025.
- Funds reported $146M of Perspective Therapeutics stock for Q2 2025, up 52% quarter-over-quarter.
- 9 funds opened new Perspective Therapeutics positions in Q2 2025 and 24 closed out, a net change of -15 holders.
- The largest Perspective Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $6.56M added.
- The largest Perspective Therapeutics seller in Q2 2025 was Deerfield Management, an estimated $6.03M sold.
Based on aggregated 13F filings for Q2 2025.